This work is the basis for AlloMap TM
molecular expression testing, a service provided by XDx through its
clinical laboratory in South San Francisco, California. AlloMap testing
provides transplant physicians a new tool for post-cardiac transplant
patient management. The lab received CLIA (Clinical Laboratory
Improvements Amendments) certification in November 2004. AlloMap
testing is being incorporated into clinical practice at leading U.S.
car...
more
Our Mission
Improve patient care by
developing molecular diagnostics that translate an individual's immune
status into clinically actionable information.
About XDx
Founded in 2000, XDx is a molecular diagnostics company based in South
San Francisco, Calif. Setting the stage for a new era in personalized
medicine, XDx is one of the first companies to develop and
commercialize practical applications built on insights from the Human
Genome Project. The company has developed a proprietary new method for
noninvasively monitoring the immune system by measuring gene expression
in a patient’s peripheral blood. The technology offers the potential to
decrease healthcare costs and significantly improve the quality of life
for patients with a variety of life-threatening or life-altering,
immune-mediated diseases.
This work is the basis for AlloMapTM
molecular expression testing, a service provided by XDx through its
clinical laboratory in South San Francisco, California. AlloMap testing
provides transplant physicians a new tool for post-cardiac transplant
patient management. The lab received CLIA (Clinical Laboratory
Improvements Amendments) certification in November 2004. AlloMap
testing is being incorporated into clinical practice at leading U.S.
cardiac transplant centers.
XDx's First Market: Post-Cardiac Transplant Patient Management
Worldwide, approximately 4,500 cardiac transplants are performed
annually and the approximately 30,000 patients living with transplants
visit their physician an aggregate of over 100,000 times per year.
These visits are vital to monitor whether the
patient's immune system is rejecting the transplanted heart and whether
the patient is able to tolerate the powerful immunosuppressive drugs
that attempt to prevent the immune system from attacking and rejecting
the new heart.
Current clinical practice calls for multiple cardiac
biopsies, as many as 10 or more, in the first year post-transplant,
where pathologists look for microscopic evidence of rejection. These
invasive procedures are necessary despite the fact that over 75% of the
time, they provide a negative result- the patient's immune system is
not rejecting the transplanted heart.
While cardiac biopsy is the gold standard for monitoring
transplant rejection, there is a critical need for a better tool. XDx
is working to introduce AlloMap as that better tool to monitor
rejection.
Broad Based Technology Platform
The AlloMap molecular expression technology developed and implemented
by XDx in heart transplant patient management may be broadly applicable
to other diseases that involve the immune system. Lung, kidney, liver,
pancreas and bone marrow transplantation are all complicated by
rejection mediated through the immune system. XDx also foresees
opportunities in common autoimmune and chronic inflammatory diseases
that involve activation or dysfunction of the immune system.
